Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Obatoclax Mesylate (GX15-070) Chemical Structure

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • In vivo antitumor efficacies of AZD2281 and GX15-070 alone or in combination in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 lm-thick slides for H&E, PCNA, and CD34 staining.

    Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Gx15-070 induces autophagy and necroptosis in TET cells. Time-course electron microscopic morphology of T1682 cells treated with Gx15-070 at the indicated concentrations. After 1-h treatment, lamellar bodies (yellow arrow) consistent with early signs of autophagy and mitochondrial structural changes with loss of cristae (orange arrow) were evident. After 6-h treatment, early signs of necroptosis with intact nuclear envelope (top panel), and mitochondrial swelling with loss of mitochondrial matrix and cytoplasm vacuolization were observed (bottom panel). After 48-h treatment, late stages of necroptotic cell death (yellow arrow) and advanced stages of autophagy (orange arrow) were evident. The bottom panel depicts advanced stage of autophagic cell death with cytoplasmic vacuolization and lamellar bound structures consistent with autophagosomes.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • ffect of Gx15-070 of mTOR pathway and on AMPKα. Effect of 6h Gx15-070 treatment on T1682 cells compared with untreated cells and cells starved for 6 h. The treatment induced a progressive reduction of p-AKT (Ser473 and Thr308) and p-RPS6 with the exception of 500 nM concentration. Progressive increase of LC3B-II and AMPKα phosphorylation was observed in Gx15-070 concentration-dependent manner.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

     

    Upregulation of A1 is crucial for resistance to ABT-737. The role of different anti-apoptotic Bcl-2 factors in determining resistance to ABT-737 was investigated, comparing the pro-apoptotic effect of ABT-737, antimycin A and obatoclax on activated (filled circles) and non-activated (open circles) BM3.3 CD8 T cells. T-cell activation induced resistance to ABT-737 and to antimycin A, but not to obatoclax, demonstrating a crucial role of A1 in this phenomenon. Percentage of cells treated with DMSO-containing vehicle is given. Half maximal inhibitory concentration (IC50) and 95% confidence interval (95% CI) are reported in the table.

    Cell Death Dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • HUH6 cells (C-H) were incubated with and without 10 ng/ml TNF-α and obatoclax at 0.1, 0.3 uM. Fewer mitochondria with an intact membrane potential were observed in JC-1 staining when obatoclax and TNF-α were added to the culture. Reddish points indicate the aggregation of JC-1 in intact mitochondria, and missing of reddish points indicate the start of apoptosis.

    Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Cell proliferation assays were carried out in SET-2 cells treated with increasing concentrations of NVP-BSK805 (empty triangles/solid line), obatoclax (filled squares/dotted line) or NVP-BSK805 in combination with a fixed obatoclax concentration of 700 nM (filled triangles/stippled line) for 72 hours.

     

     

    BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • MEF cells were treated for  24 hours with the Bcl-2 antagonists  Obatoclax Mesylate at the indicated doses.Acute survival was monitored by replacing the drug-containing media with normal media and incubating the cells until visible colonies formed.Clonogenic survival is expressed relative to the numbers of colonies formed following 24 hours incubation in normal media(lacking drugs).

     

     

    Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 μM cisplatin in the absence or in thepresence of 1 μM Obatoclax Mesylate .The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • Obataclax triggers cell death similarly in parental and ABT-737-resistant cells. Parental and ABT-R cells were treated with obataclax (Nalm-6 and Nalm-6 ABT-R: 10 uM; Reh and Reh ABT-R: 5 uM) for 18 h. (A) Cell viability was determined by trypan blue exclusion assay. (B) Mcl-1, NOXA, Bim, and b-actin as a loading control were analyzed by immunoblot. 

    Obatoclax Mesylate (GX15-070) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.
Features Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
Targets
Bcl-2 [1]
(Cell-free assay)
0.22 μM(Ki)
In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. [1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. [2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KARPAS-45 M2qwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;lZWlEPTB;MD6wNFAxOzF5IN88US=> NX;nUmhiW0GQR1XS
SK-MEL-30 NX7V[VVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfQR4oxUUN3ME2wMlAxODN3NTFOwG0> MUPTRW5ITVJ?
NALM-6 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\scYlUUUN3ME2wMlAxODN3NjFOwG0> MYXTRW5ITVJ?
KYSE-450 Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHwTWM2OD1yLkCwNFQ3QSEQvF2= NIrHXHlUSU6JRWK=
BHY MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\KWGVlUUN3ME2wMlAxODZyMTFOwG0> NFPTdG1USU6JRWK=
GR-ST NV;tcG97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjNd25nUUN3ME2wMlAxODZ2ODFOwG0> NGC5eXhUSU6JRWK=
786-0 MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMECwO|c3KM7:TR?= NV30R2Z4W0GQR1XS
C-33-A NVfYSWl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMECwPFQ5KM7:TR?= M1[y[HNCVkeHUh?=
BHT-101 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTi[VdlUUN3ME2wMlAxOTB4IN88US=> MlvxV2FPT0WU
EB2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\EfodKSzVyPUCuNFAyOThizszN MlexV2FPT0WU
G-361 Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7tTWM2OD1yLkCwNVI1KM7:TR?= MlTrV2FPT0WU
KE-37 MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMECxNlgh|ryP NXuzN5gyW0GQR1XS
MHH-PREB-1 M{i0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjhXHJlUUN3ME2wMlAxOTRizszN MWnTRW5ITVJ?
MCF7 MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMECxOVkh|ryP NV7VTG9tW0GQR1XS
LOUCY NUewdYRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwMECxO|Uh|ryP MUXTRW5ITVJ?
EW-7 NEH5VYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnezTWM2OD1yLkCwNVc2KM7:TR?= NHfUXFhUSU6JRWK=
KYSE-510 M3PCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrsPYFKSzVyPUCuNFAzOzNizszN NYXwRpp{W0GQR1XS
SK-MEL-3 NWnTV5ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS0dnhwUUN3ME2wMlAxOjZ2IN88US=> NWr4PXdsW0GQR1XS
HAL-01 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3oZpEyUUN3ME2wMlAxOjl5IN88US=> M2m3THNCVkeHUh?=
HCC2998 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn2TWM2OD1yLkCwN|M2KM7:TR?= MmDmV2FPT0WU
A375 NG[zUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMECzOUDPxE1? MYDTRW5ITVJ?
MZ7-mel NF20NoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\lVJd[UUN3ME2wMlAxOzl7IN88US=> M1XobXNCVkeHUh?=
SH-4 NF\mWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;YTWM2OD1yLkCwOFE4KM7:TR?= Ml3PV2FPT0WU
HT-144 M4Du[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjwTWM2OD1yLkCwOFMh|ryP NFv6U|ZUSU6JRWK=
KYSE-140 NGnOdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnEZZBKSzVyPUCuNFA1OzVizszN MWfTRW5ITVJ?
PSN1 NGThZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLqTWM2OD1yLkCwOFY4KM7:TR?= NF6zZ2ZUSU6JRWK=
COLO-679 MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfnTWM2OD1yLkCwOFk5KM7:TR?= NVq0UHl2W0GQR1XS
SW620 MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HibGlEPTB;MD6wNFUyOSEQvF2= NVmwVVh3W0GQR1XS
HGC-27 NVrYc2RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXMcFlLUUN3ME2wMlAxPTJ2IN88US=> MV3TRW5ITVJ?
IGROV-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{juT2lEPTB;MD6wNFYh|ryP NHjxfpFUSU6JRWK=
IGR-1 MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfUXJpKSzVyPUCuNFA3ODFizszN MXXTRW5ITVJ?
EW-1 M1\QN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL2VWZwUUN3ME2wMlAxPjVzIN88US=> NGfhPGVUSU6JRWK=
769-P M3rKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfBRmsyUUN3ME2wMlAxPjd6IN88US=> NFHmNGNUSU6JRWK=
HN NXHhb2RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y5NWlEPTB;MD6wNFY4QSEQvF2= NELBZo1USU6JRWK=
SIG-M5 M1nHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMEC3NUDPxE1? Mn;QV2FPT0WU
IST-MEL1 NILoSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnVc2szUUN3ME2wMlAxQDF6IN88US=> MXXTRW5ITVJ?
ST486 NIDlW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zjfWlEPTB;MD6wNFgzPSEQvF2= MoDKV2FPT0WU
ES7 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mom3TWM2OD1yLkCwPFQ3KM7:TR?= M2i0ZXNCVkeHUh?=
GAK M3rpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMEC4OFgh|ryP NED1PGpUSU6JRWK=
BB30-HNC M2W4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMEC4OVgh|ryP NFS2OpVUSU6JRWK=
IPC-298 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHOSGhKSzVyPUCuNFA6OjdizszN NETNdmxUSU6JRWK=
NKM-1 M1fKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXUTWM2OD1yLkCwPVczKM7:TR?= NHPI[3lUSU6JRWK=
RKO NWLqcolYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL6TWM2OD1yLkCxNFQ1KM7:TR?= MmXrV2FPT0WU
ACN NUHtSVVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TPWGlEPTB;MD6wNVE{OSEQvF2= M{HKZ3NCVkeHUh?=
SW1417 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HuXmlEPTB;MD6wNVIzPSEQvF2= MVLTRW5ITVJ?
SR M1;ybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofhTWM2OD1yLkCxNlM2KM7:TR?= MXjTRW5ITVJ?
SNG-M NIXiW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMEGzNVch|ryP MXzTRW5ITVJ?
CAL-12T M4jicmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vkTGlEPTB;MD6wNVM1PiEQvF2= MX3TRW5ITVJ?
HSC-3 NHPHOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjGeIdLUUN3ME2wMlAyOzV3IN88US=> M1mwPXNCVkeHUh?=
DOHH-2 NYHhR|BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf0bpQ6UUN3ME2wMlAyPDF{IN88US=> M4jtXnNCVkeHUh?=
NB69 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMEG1OlUh|ryP MmPEV2FPT0WU
LC-2-ad MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3QUZBEUUN3ME2wMlAyPThzIN88US=> MWrTRW5ITVJ?
RVH-421 M3nvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMEG2O|Qh|ryP MoTXV2FPT0WU
TGW MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rjb2lEPTB;MD6wNVc{QSEQvF2= M3TqNHNCVkeHUh?=
HCC1569 NX6xcXVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PYXWlEPTB;MD6wNVc6PyEQvF2= NF\u[|BUSU6JRWK=
CAL-85-1 NU\OUW0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEG4N|Ih|ryP NGfne5RUSU6JRWK=
RPMI-8402 NYfjUmNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\wUZRKSzVyPUCuNFE5PThizszN NYjDO|dZW0GQR1XS
THP-1 MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jVU2lEPTB;MD6wNVk6QCEQvF2= Mmf4V2FPT0WU
ONS-76 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMEKwN|Yh|ryP NEjyWI5USU6JRWK=
A2780 NY\PWZBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTsTWM2OD1yLkCyNFc6KM7:TR?= MULTRW5ITVJ?
RPMI-2650 NUT3ZmRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMEKyPVYh|ryP Ml73V2FPT0WU
MEL-HO MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMEKzOFgh|ryP M3XlOnNCVkeHUh?=
MC-CAR NGTQc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFv3UFNKSzVyPUCuNFI{PTZizszN MnzSV2FPT0WU
HSC-2 M{P2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:2TWM2OD1yLkCyOFY3KM7:TR?= MnHvV2FPT0WU
MEL-JUSO NHXsenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD2TWM2OD1yLkCyOFc{KM7:TR?= Ml;MV2FPT0WU
CAL-62 MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7ofVc3UUN3ME2wMlAzPjB{IN88US=> MWrTRW5ITVJ?
DMS-273 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEK4OFch|ryP MmqyV2FPT0WU
S-117 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rxW2lEPTB;MD6wNlkxPiEQvF2= Mn\kV2FPT0WU
SUP-T1 M3XwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPpNZhlUUN3ME2wMlAzQTR7IN88US=> MV;TRW5ITVJ?
MZ2-MEL NHz3SpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMEK5OVkh|ryP MY\TRW5ITVJ?
KYSE-270 NGXpW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTVTWM2OD1yLkCyPVc3KM7:TR?= M{PpVnNCVkeHUh?=
CMK NHrOWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMEOwNlMh|ryP NFrLUVhUSU6JRWK=
8505C NYjkT|lWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXwTWM2OD1yLkCzNFQh|ryP M4rCVXNCVkeHUh?=
NUGC-3 MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzGTWM2OD1yLkCzNFQ5KM7:TR?= MkSxV2FPT0WU
A101D NXzrWWpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMEOwOVUh|ryP NW\OV2hbW0GQR1XS
G-401 M13mWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7QcVRKSzVyPUCuNFMxQTNizszN Mn;tV2FPT0WU
OVCAR-8 MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nGT2lEPTB;MD6wN|ExPyEQvF2= NEPkZphUSU6JRWK=
IMR-5 M3ywS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr6T2V2UUN3ME2wMlA{OjR2IN88US=> M2rSd3NCVkeHUh?=
DoTc2-4510 NYnRVlBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DGdWlEPTB;MD6wN|M6OyEQvF2= NGjEOYdUSU6JRWK=
HOS M13JV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIOx[YlKSzVyPUCuNFM1PzNizszN MknqV2FPT0WU
HEC-1 NEDPTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPPTWM2OD1yLkCzOlgh|ryP M4mzXHNCVkeHUh?=
SW756 NXXOXIlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYq4ZWRPUUN3ME2wMlA{QDJzIN88US=> NXrRZmxSW0GQR1XS
NCI-H64 NWfKXFJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfmRpg3UUN3ME2wMlA{QDR{IN88US=> MVLTRW5ITVJ?
EW-16 NVnNVmxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMEO5NFkh|ryP NXmweXh5W0GQR1XS
CAL-51 NV[3PGFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMESwNFUh|ryP MojhV2FPT0WU
KYSE-150 NYP0O3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMESwNVEh|ryP M13tW3NCVkeHUh?=
SW1710 MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMESwNVgh|ryP M{nOVnNCVkeHUh?=
HuP-T4 M2izcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nOUWlEPTB;MD6wOFEyQCEQvF2= NXPUS4ZwW0GQR1XS
LB373-MEL-D M4L0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzQTWM2OD1yLkC0NlMzKM7:TR?= MXrTRW5ITVJ?
EW-13 M123S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK5NVBLUUN3ME2wMlA1PDB4IN88US=> NF:zNJZUSU6JRWK=
HT-29 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\UVGlEPTB;MD6wOFQ6KM7:TR?= NXPQbYhvW0GQR1XS
SCC-25 M13WXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;RTWM2OD1yLkC0OFk1KM7:TR?= NFjSbW5USU6JRWK=
REH NVTvblRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITUdHVKSzVyPUCuNFQ3OzVizszN M4rKSHNCVkeHUh?=
L-363 NIn0WppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMES2O|kh|ryP NHHiOXFUSU6JRWK=
NCI-H1770 NYm5fWlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfRVnhKSzVyPUCuNFQ3QTdizszN NUXzeHBmW0GQR1XS
CHL-1 M1iwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMES4OVch|ryP NGSxRmhUSU6JRWK=
ES1 MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwMES4PFUh|ryP MV7TRW5ITVJ?
SCC-15 NYrPNFRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMES5NFIh|ryP M2LRVXNCVkeHUh?=
MRK-nu-1 MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMES5N|Yh|ryP NYrVWHpHW0GQR1XS
PF-382 NUe0O|VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLzUnF1UUN3ME2wMlA1QTN7IN88US=> NWXveXROW0GQR1XS
COLO-680N MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\UTWM2OD1yLkC1NFQ4KM7:TR?= NFv4N3ZUSU6JRWK=
LK-2 NIXVTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXSTWM2OD1yLkC1NFY{KM7:TR?= NUPMVYptW0GQR1XS
NCI-H2342 NGjYTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[2VGlEPTB;MD6wOVEyPyEQvF2= NXLkRW92W0GQR1XS
HMV-II M3noWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT1TWM2OD1yLkC1NlM6KM7:TR?= MX;TRW5ITVJ?
PC-14 M{W4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33NVWlEPTB;MD6wOVI2OiEQvF2= Mn3GV2FPT0WU
COLO-320-HSR NYnQ[Hh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrkUmlKSzVyPUCuNFUzQDlizszN MUPTRW5ITVJ?
697 NYHh[IFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7qXo9QUUN3ME2wMlA2OzJ|IN88US=> MYjTRW5ITVJ?
NEC8 M{mwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMEW1PUDPxE1? M4qwO3NCVkeHUh?=
LCLC-97TM1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\RS2lEPTB;MD6wOVU6PCEQvF2= NGnIV4pUSU6JRWK=
Daoy NHm0R4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnOTWM2OD1yLkC1OlE3KM7:TR?= NUTUNmMzW0GQR1XS
ETK-1 NHq5cGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMEW2O|Ih|ryP MX3TRW5ITVJ?
A388 MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDoTWM2OD1yLkC1Olk2KM7:TR?= MlW5V2FPT0WU
COLO-205 NX31fnpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjhTWM2OD1yLkC1O|E3KM7:TR?= NFy1bWFUSU6JRWK=
SK-PN-DW NHGzWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPaeFFpUUN3ME2wMlA2PzJ7IN88US=> MnzwV2FPT0WU
SF268 NWn4cY1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrF[HVFUUN3ME2wMlA2PzV4IN88US=> NFvPVoVUSU6JRWK=
OCI-AML2 NGnId|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\sTFF1UUN3ME2wMlA2Pzd5IN88US=> MlfwV2FPT0WU
GAMG MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfoSVhKSzVyPUCuNFU5KM7:TR?= NIfqcINUSU6JRWK=
BCPAP NXS3VnNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jwcWlEPTB;MD6wOVg6OiEQvF2= MV7TRW5ITVJ?
BC-1 M1;GcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jENWlEPTB;MD6wOlAzOiEQvF2= MljTV2FPT0WU
IA-LM NHzJZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOxUoZVUUN3ME2wMlA3ODV|IN88US=> MVrTRW5ITVJ?
NCI-H1299 NXmydJZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzvOI5zUUN3ME2wMlA3OTNizszN MnPvV2FPT0WU
COR-L23 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLFTWM2OD1yLkC2NVM1KM7:TR?= MnmxV2FPT0WU
KYSE-180 NVT4XZVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7MUpNKSzVyPUCuNFYyPDJizszN MVzTRW5ITVJ?
LOXIMVI Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnryTWM2OD1yLkC2NVg5KM7:TR?= MkC5V2FPT0WU
BL-41 NHHVVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nmTGlEPTB;MD6wOlIyQSEQvF2= NIHYdFZUSU6JRWK=
BL-70 NV7P[5VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwME[zNFIh|ryP MWTTRW5ITVJ?
NOS-1 MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K3bmlEPTB;MD6wOlQyOSEQvF2= MW\TRW5ITVJ?
NB13 M1Po[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\xTWM2OD1yLkC2OFIyKM7:TR?= NWLaOXY2W0GQR1XS
CAL-27 MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwME[0OlQh|ryP MXvTRW5ITVJ?
CA46 MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\PZZBKUUN3ME2wMlA3PTN5IN88US=> M{HHenNCVkeHUh?=
SW962 NIW4VHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwME[1Olkh|ryP NFPvT3JUSU6JRWK=
NCI-H226 M4rBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rZU2lEPTB;MD6wOlY{OiEQvF2= NXrLOYc6W0GQR1XS
KYSE-70 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwME[5OFUh|ryP M3nFcnNCVkeHUh?=
Daudi NWjI[o5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K0VmlEPTB;MD6wO|A5OSEQvF2= NW\vc41QW0GQR1XS
SW626 NHLKfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi1TWM2OD1yLkC3NlA1KM7:TR?= MWPTRW5ITVJ?
ESS-1 MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEeyOFYh|ryP MlfVV2FPT0WU
YT MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\NTWM2OD1yLkC3N|Q2KM7:TR?= NFHYe29USU6JRWK=
P12-ICHIKAWA M3TMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPHT4NKSzVyPUCuNFc{PDlizszN MWHTRW5ITVJ?
BxPC-3 NGHyZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13aS2lEPTB;MD6wO|Q2QCEQvF2= MXjTRW5ITVJ?
CTV-1 NXPTRlhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnmTWM2OD1yLkC3OVE4KM7:TR?= NXrTTo5GW0GQR1XS
MLMA MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMEe1N|Qh|ryP MmjkV2FPT0WU
WSU-NHL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMEe1OVQh|ryP MXvTRW5ITVJ?
CTB-1 Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7OXpppUUN3ME2wMlA4PTh6IN88US=> NFGzNpZUSU6JRWK=
MMAC-SF M2P3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml22TWM2OD1yLkC3OlY5KM7:TR?= MUPTRW5ITVJ?
8-MG-BA Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[zTWM2OD1yLkC3PFAyKM7:TR?= Ml\CV2FPT0WU
NCI-H358 Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMEe4O|kh|ryP NHrU[nJUSU6JRWK=
BFTC-905 MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HvNWlEPTB;MD6wO|kxQSEQvF2= M1XVXHNCVkeHUh?=
NCI-H727 M1;iO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMEiwOVMh|ryP NW\Ec4ZZW0GQR1XS
CHP-212 NFfKXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3njcWlEPTB;MD6wPFA6PSEQvF2= Mm\xV2FPT0WU
HOP-62 NF3LbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fWUmlEPTB;MD6wPFI1PSEQvF2= MWfTRW5ITVJ?
CESS M1nhWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLhXGVKSzVyPUCuNFgzPjlizszN NXq1[GxQW0GQR1XS
HuCCT1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTDTWM2OD1yLkC4N|M{KM7:TR?= NWfYbpN3W0GQR1XS
DEL NH3pWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnINnRKSzVyPUCuNFg{PDdizszN M4[0WHNCVkeHUh?=
5637 NHWyNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMEizOlch|ryP M1m3SXNCVkeHUh?=
RS4-11 NYPFNo94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PDb2lEPTB;MD6wPFQ6PyEQvF2= M4X5bnNCVkeHUh?=
KURAMOCHI M4LUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37vWmlEPTB;MD6wPFUxQSEQvF2= MUHTRW5ITVJ?
A427 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMEi1NVIh|ryP MnvIV2FPT0WU
A3-KAW NGTvb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkGzTWM2OD1yLkC4OVY3KM7:TR?= MVfTRW5ITVJ?
LS-123 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH36TpBKSzVyPUCuNFg4OTlizszN M3q2dXNCVkeHUh?=
LoVo Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjtUllKSzVyPUCuNFg4OiEQvF2= NYexfGFJW0GQR1XS
PA-1 NX\6[GR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMEi3Olkh|ryP M1;BU3NCVkeHUh?=
CP50-MEL-B Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwMEi3PVMh|ryP MkO0V2FPT0WU
A431 M{Tjcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nnV2lEPTB;MD6wPFgxOSEQvF2= M17qOXNCVkeHUh?=
HCT-116 NGSxXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofTTWM2OD1yLkC4PFAzKM7:TR?= NWOxV2s1W0GQR1XS
A4-Fuk Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnZc41KSzVyPUCuNFg6PDdizszN MmDvV2FPT0WU
RPMI-6666 NH;uRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMEi5Olch|ryP NHTOSWdUSU6JRWK=
Calu-6 M3r6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17xTWlEPTB;MD6wPVAzQSEQvF2= MULTRW5ITVJ?
KMOE-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMEmwN|kh|ryP MYTTRW5ITVJ?
A704 M{TYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfHTWM2OD1yLkC5NVUh|ryP NUjUUmhkW0GQR1XS
HO-1-N-1 M2XmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG4TWM2OD1yLkC5NlQ6KM7:TR?= NEeyW2JUSU6JRWK=
NCI-H2122 M3TGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnmV5BKSzVyPUCuNFk{PzhizszN MnvmV2FPT0WU
U-698-M M{PmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrETWM2OD1yLkC5OFA6KM7:TR?= MYfTRW5ITVJ?
IST-SL2 NIDrVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDOWYpKSzVyPUCuNFk1PjhizszN MkOzV2FPT0WU
TE-10 NIrsRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PVVmlEPTB;MD6wPVU5PCEQvF2= M4\0[HNCVkeHUh?=
PANC-03-27 M{XGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfKcG5PUUN3ME2wMlA6PjdzIN88US=> MlnhV2FPT0WU
KYSE-410 NIfaUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H6[2lEPTB;MD6wPVc6PyEQvF2= NEnTc4lUSU6JRWK=
TE-8 M2jNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMEm4PFUh|ryP NV7mblVJW0GQR1XS
MN-60 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r0bWlEPTB;MD6wPVg6PyEQvF2= M2LGfXNCVkeHUh?=
NCI-H460 NYGxd5Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvITWM2OD1yLkGwNFkh|ryP Mor1V2FPT0WU
LB771-HNC NYn4elh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrlc2RtUUN3ME2wMlExOjV3IN88US=> MlT0V2FPT0WU
ES4 NV7zO5N2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMUCyOlQh|ryP MnKyV2FPT0WU
HUTU-80 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHe1U5pKSzVyPUCuNVA{PjVizszN MmqyV2FPT0WU
647-V MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj5ZmRKSzVyPUCuNVA1ODhizszN MnPMV2FPT0WU
HTC-C3 MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PiN2lEPTB;MD6xNFQ{OiEQvF2= NF7jVoNUSU6JRWK=
NTERA-S-cl-D1 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DLfWlEPTB;MD6xNFQ1QCEQvF2= MnfpV2FPT0WU
A2058 NXX6eHJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMUC2OVUh|ryP M1HSenNCVkeHUh?=
MZ1-PC NHL6N|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMUC4N{DPxE1? M1;MSnNCVkeHUh?=
J82 NWXqOo5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMUC4PFQh|ryP Ml3DV2FPT0WU
ARH-77 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDqTWM2OD1yLkGxJO69VQ>? NFjNe5lUSU6JRWK=
Ca9-22 MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17FemlEPTB;MD6xNVEzQCEQvF2= NFTOU2xUSU6JRWK=
NCI-H1648 M4\IWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMUGyPFYh|ryP MY\TRW5ITVJ?
MC116 M4\SZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvhNnRKSzVyPUCuNVE{OzdizszN MXzTRW5ITVJ?
EoL-1-cell Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\tNoxKSzVyPUCuNVE1PjdizszN MoDvV2FPT0WU
PANC-10-05 NI[0c3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HkOWlEPTB;MD6xNVQ6OSEQvF2= M1fkbXNCVkeHUh?=
SF539 NFLocZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLqeXVqUUN3ME2wMlEyPjF4IN88US=> M3\YZnNCVkeHUh?=
ES8 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j3WmlEPTB;MD6xNVY{OyEQvF2= NUHQeWZWW0GQR1XS
NCI-H810 NIPRT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLCTWM2OD1yLkGxOlY1KM7:TR?= NYj4RYN2W0GQR1XS
J-RT3-T3-5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[1TWM2OD1yLkGxO|Uh|ryP MX3TRW5ITVJ?
NY MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDXbVBKSzVyPUCuNVE5OTdizszN M3W3eXNCVkeHUh?=
NCI-SNU-1 NUfvWYZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e5d2lEPTB;MD6xNlE1QCEQvF2= NHHoO2JUSU6JRWK=
EFM-19 NXy1XZpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGizV|NKSzVyPUCuNVI{PzRizszN MkjlV2FPT0WU
HCC1806 M4TleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMUKzPFMh|ryP MoT5V2FPT0WU
HCE-T M{PLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf5VplTUUN3ME2wMlEzPTNzIN88US=> NXSyVmtNW0GQR1XS
HT-1376 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S3PGlEPTB;MD6xNlY3QCEQvF2= MX\TRW5ITVJ?
BE-13 NX3aV2dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HrNmlEPTB;MD6xNlg3PiEQvF2= NHXzeY9USU6JRWK=
NCI-H520 Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMUK4Olch|ryP MnzIV2FPT0WU
SK-MES-1 Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrrc4JLUUN3ME2wMlEzQTF|IN88US=> MmLEV2FPT0WU
SNU-423 M1LhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPkTWM2OD1yLkGyPVE1KM7:TR?= MYXTRW5ITVJ?
Ramos-2G6-4C10 NUL5OXpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfPUIVzUUN3ME2wMlEzQTF4IN88US=> NVT5b5l3W0GQR1XS
EW-18 M1PwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMUOwNlYh|ryP NH2zOnFUSU6JRWK=
NCI-H2087 NIH6TGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DySGlEPTB;MD6xN|AzPyEQvF2= NUK1PWhJW0GQR1XS
COLO-792 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3myU2lEPTB;MD6xN|E3PSEQvF2= NWD2RoZnW0GQR1XS
QIMR-WIL M3[4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3XTWM2OD1yLkGzNlI{KM7:TR?= NEfyVmtUSU6JRWK=
ACHN NITVcmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPtW5g1UUN3ME2wMlE{OjR5IN88US=> MnPDV2FPT0WU
RPMI-8866 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMUOyOlEh|ryP MWnTRW5ITVJ?
SK-LU-1 M2C4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHHc3lLUUN3ME2wMlE{PDR7IN88US=> M1TmeHNCVkeHUh?=
SK-UT-1 NEfBOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMUO2Nlgh|ryP Mom4V2FPT0WU
MFE-296 NYPrUVVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTSTWM2OD1yLkGzPFY1KM7:TR?= NVOwOnhjW0GQR1XS
RD NX3DRo0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HoZ2lEPTB;MD6xN|k6PyEQvF2= NEnOUnJUSU6JRWK=
LS-411N NU\pNllPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4mwV2lEPTB;MD6xOFI6PSEQvF2= NXW3O3RIW0GQR1XS
NCI-H747 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMUSzJO69VQ>? M1;FNHNCVkeHUh?=
ES6 NFLBXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMUSzOkDPxE1? MlewV2FPT0WU
TE-1 M1jpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX3PGk2UUN3ME2wMlE1PDB5IN88US=> NIjj[mdUSU6JRWK=
SJSA-1 M325Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEiwPXhKSzVyPUCuNVQ4ODdizszN M1TweXNCVkeHUh?=
NCI-H1355 MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nJT2lEPTB;MD6xOVI6OyEQvF2= M{HqfHNCVkeHUh?=
HEL MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT3[YhKSzVyPUCuNVU1PDdizszN MonlV2FPT0WU
639-V MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC4SopuUUN3ME2wMlE2PTl4IN88US=> M1;2SXNCVkeHUh?=
AN3-CA Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvwOHFKSzVyPUCuNVU3OzlizszN MnXmV2FPT0WU
SK-MEL-2 NV;iN3dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGexZmRKSzVyPUCuNVU3PjhizszN NYDHfFJKW0GQR1XS
SW872 NFnONGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrUO5N2UUN3ME2wMlE3ODR{IN88US=> MUnTRW5ITVJ?
DU-4475 NYO1WGxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLDU|ExUUN3ME2wMlE3OTZ{IN88US=> NYDYWHYxW0GQR1XS
YKG-1 NUnYWFl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnRe5lQUUN3ME2wMlE3Ojd|IN88US=> MlLUV2FPT0WU
GT3TKB NXPnZo4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPoS5ZKSzVyPUCuNVYzQDNizszN M4H3WHNCVkeHUh?=
GB-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofnTWM2OD1yLkG2OFI1KM7:TR?= Mn[1V2FPT0WU
KARPAS-422 NF\ONG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHmyW4VKSzVyPUCuNVY2PzRizszN MUXTRW5ITVJ?
ATN-1 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMU[2OVYh|ryP MUHTRW5ITVJ?
HLE MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfsSGN2UUN3ME2wMlE3QDd5IN88US=> NGHUfG9USU6JRWK=
D-542MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPkfWhKSzVyPUCuNVY6QDZizszN MlzVV2FPT0WU
EB-3 NVK2XJlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPBTXVKSzVyPUCuNVc{OSEQvF2= MYTTRW5ITVJ?
HCC1143 NVW4XHpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjaWmlbUUN3ME2wMlE4Ozl4IN88US=> MX3TRW5ITVJ?
DJM-1 NETxRoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF60cIlKSzVyPUCuNVc1PTFizszN NUfl[FI2W0GQR1XS
BT-474 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHKZY9KSzVyPUCuNVc1QDlizszN NVTpWWloW0GQR1XS
BB65-RCC NG\lNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX4TWM2OD1yLkG3OVQ2KM7:TR?= NXHn[|FtW0GQR1XS
NCI-H292 M{n2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPwdXNKSzVyPUCuNVc3ODFizszN M4nLbXNCVkeHUh?=
MKN28 NGXmfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfR[HRKSzVyPUCuNVc3PTNizszN MXPTRW5ITVJ?
TK10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL6So55UUN3ME2wMlE4PzB{IN88US=> MUjTRW5ITVJ?
TYK-nu M3HsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3ZcIRKSzVyPUCuNVc6PDlizszN NIPZdZhUSU6JRWK=
8305C MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\iU29KSzVyPUCuNVc6PzFizszN MnnqV2FPT0WU
MV-4-11 M1fFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHGTWM2OD1yLkG3PVc4KM7:TR?= MofiV2FPT0WU
NCI-H522 NYXaZotFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULyO254UUN3ME2wMlE5ODl2IN88US=> NH7acphUSU6JRWK=
Hs-578-T MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMUiyPVIh|ryP MkfmV2FPT0WU
LCLC-103H MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMUi1Nlch|ryP NGDBWY1USU6JRWK=
MHH-ES-1 NXXXTXI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Sz[2lEPTB;MD6xPFYzQSEQvF2= Mmr4V2FPT0WU
NCI-H441 Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\s[odKSzVyPUCuNVkyPDhizszN MYPTRW5ITVJ?
AM-38 NGPqPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvrTWM2OD1yLkG5NlI2KM7:TR?= NV;JVHZHW0GQR1XS
SW1783 NG\SOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXuTG9KSzVyPUCuNVk{ODVizszN NI\Ne45USU6JRWK=
SK-HEP-1 NFTteppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW0R4M3UUN3ME2wMlE6PjN5IN88US=> NXfEO|c{W0GQR1XS
OAW-28 NHvLWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\nTWM2OD1yLkKwNVc5KM7:TR?= NHH0b3NUSU6JRWK=
TE-15 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;2SHJ7UUN3ME2wMlIxOjV{IN88US=> MnzMV2FPT0WU
HCE-4 M{DaXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfNOHdpUUN3ME2wMlIxOjh2IN88US=> NEnpeGhUSU6JRWK=
JiyoyeP-2003 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVeyeIhvUUN3ME2wMlIxOzN4IN88US=> NIHH[lRUSU6JRWK=
OVCAR-4 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMkC2Nlgh|ryP NF7tZnZUSU6JRWK=
SNU-449 NYTPSYdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;PNmlEPTB;MD6yNFc6PyEQvF2= M2fn[XNCVkeHUh?=
SBC-5 NYX5UG9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEm2O5lKSzVyPUCuNlEzOTVizszN Mn7wV2FPT0WU
T84 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMkGyOFgh|ryP NF\6VpdUSU6JRWK=
LP-1 NEPteJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXZTWM2OD1yLkKxN|AzKM7:TR?= NYDVc2JJW0GQR1XS
MG-63 NG\6TYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHPOHhKSzVyPUCuNlE{QDJizszN M{npXnNCVkeHUh?=
OAW-42 M2DKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMkG0O|gh|ryP Mn7BV2FPT0WU
L-540 NFHpOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMkG1PVgh|ryP NHHDNnJUSU6JRWK=
RH-1 NYO2c3FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMkKyOFIh|ryP Mmq0V2FPT0WU
HCT-15 NHTDUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jhZ2lEPTB;MD6yNlQ5PCEQvF2= MXvTRW5ITVJ?
OCUB-M M1;iU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkm2TWM2OD1yLkKyOFg5KM7:TR?= Ml;yV2FPT0WU
GP5d MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnpN|lKSzVyPUCuNlI2OjhizszN NVzBcI55W0GQR1XS
NCI-H2030 MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3flXGlEPTB;MD6yNlc{PCEQvF2= MofoV2FPT0WU
ML-2 NXrEZWlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn4OnFKSzVyPUCuNlI5QDlizszN NEnC[5ZUSU6JRWK=
CAL-39 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwMkK5N|Yh|ryP MmPvV2FPT0WU
MIA-PaCa-2 NVnjZ|VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX1TWM2OD1yLkKzNlg4KM7:TR?= M{fsVHNCVkeHUh?=
TE-9 NWX6NWJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL5dIRKSzVyPUCuNlM{OiEQvF2= NIjuSVdUSU6JRWK=
LB2518-MEL NFnkWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDjTWM2OD1yLkKzN|czKM7:TR?= NHnJXmpUSU6JRWK=
DB Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3no[GlEPTB;MD6yN|Q{QCEQvF2= M3HJ[nNCVkeHUh?=
NCI-H596 MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17tU2lEPTB;MD6yN|U4OSEQvF2= M4njR3NCVkeHUh?=
SW1990 MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzHNIpFUUN3ME2wMlI{QTR4IN88US=> MWDTRW5ITVJ?
P30-OHK M2LKVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMkSwOUDPxE1? NI\Jd|lUSU6JRWK=
ALL-PO NU\HUJRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjqenNDUUN3ME2wMlI1OTZ7IN88US=> MXjTRW5ITVJ?
Saos-2 M3Pp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP4TWM2OD1yLkK0OVcyKM7:TR?= M1jSbHNCVkeHUh?=
MFH-ino NYHuNZpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrDR|hKSzVyPUCuNlQ3QTJizszN MoTGV2FPT0WU
OE33 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PFTmlEPTB;MD6yOVEyKM7:TR?= NYHS[nVCW0GQR1XS
Calu-3 M3X0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Xy[GlEPTB;MD6yOVI6PyEQvF2= MX7TRW5ITVJ?
HT NGTaUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTrUmFKSzVyPUCuNlU3OjFizszN MmPaV2FPT0WU
LXF-289 NXTTcYZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMkW5PFQh|ryP MnfOV2FPT0WU
KGN MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMk[wPFkh|ryP NYDicVNRW0GQR1XS
NCI-H1417 NX3HNpl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HlN2lEPTB;MD6yOlUzPCEQvF2= NXW0em8{W0GQR1XS
SF126 NGq0dGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMkezNFIh|ryP M{HxRnNCVkeHUh?=
SAS MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLyS4R{UUN3ME2wMlI4OzB6IN88US=> M3vydnNCVkeHUh?=
22RV1 MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMkezO|gh|ryP NU\Fc2g3W0GQR1XS
GI-1 NE[x[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zreGlEPTB;MD6yO|Q5PyEQvF2= MV\TRW5ITVJ?
ES3 NVPYPHVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS0TWM2OD1yLkK3O|Y{KM7:TR?= MonLV2FPT0WU
NB1 M{DlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\ReFFWUUN3ME2wMlI4QDd4IN88US=> NHvCfW1USU6JRWK=
NCI-H650 Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMkizNFIh|ryP MUHTRW5ITVJ?
IST-MES1 M4PSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMki1OVQh|ryP NES0UVhUSU6JRWK=
UM-UC-3 M2[3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i1TWlEPTB;MD6yPVE1KM7:TR?= NH3zeoZUSU6JRWK=
CAL-120 NIjrSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\NT2lEPTB;MD6yPVY{OSEQvF2= NWrNVFdIW0GQR1XS
UACC-62 M4LTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwM{CyOFEh|ryP M{faV3NCVkeHUh?=
TE-11 M{\1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfUbIJoUUN3ME2wMlMxOjR7IN88US=> NHuyNnJUSU6JRWK=
MKN1 NFzPOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwM{CzOkDPxE1? MVjTRW5ITVJ?
KS-1 NWjUN4pyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwM{C1NlYh|ryP NWP0Z5diW0GQR1XS
GCIY NWfT[VlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXkb5ZPUUN3ME2wMlMyODB{IN88US=> MoHHV2FPT0WU
OVCAR-5 M1f6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LWZ2lEPTB;MD6zNVExPiEQvF2= Mn;KV2FPT0WU
U-266 NGWzS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwM{GxOFch|ryP M2PRbHNCVkeHUh?=
Calu-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXofYJyUUN3ME2wMlMyOjh7IN88US=> M1LjSXNCVkeHUh?=
SK-LMS-1 NHHsc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlezTWM2OD1yLkOxOFI6KM7:TR?= Mni5V2FPT0WU
COLO-741 M3jtWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDzbXZKSzVyPUCuN|E3OTRizszN NVXOd4V{W0GQR1XS
RPMI-8226 NIjvSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPaV|VKSzVyPUCuN|E3PDFizszN NUjKV2JoW0GQR1XS
KM12 M2\xOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SweGlEPTB;MD6zNVg{KM7:TR?= MVjTRW5ITVJ?
NMC-G1 MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{KwSWlEPTB;MD6zNVg3KM7:TR?= MWjTRW5ITVJ?
SJRH30 Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTBcmVWUUN3ME2wMlMzODV{IN88US=> NX;zN5dJW0GQR1XS
COR-L105 M4HHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LNbGlEPTB;MD6zNlIyQCEQvF2= MX3TRW5ITVJ?
IM-9 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr4ZlFKSzVyPUCuN|MxOjFizszN MWXTRW5ITVJ?
TE-12 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnCT5Z[UUN3ME2wMlM{OzF5IN88US=> MXzTRW5ITVJ?
KG-1 NHzCZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\2VmtKSzVyPUCuN|M1OzJizszN MliyV2FPT0WU
U251 MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfoTWM2OD1yLkOzOFU3KM7:TR?= MUHTRW5ITVJ?
EFO-27 M2rMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwM{O5OVEh|ryP MXjTRW5ITVJ?
EW-24 M1PuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkSyTWM2OD1yLkOzPVg1KM7:TR?= NIP1OoVUSU6JRWK=
SF295 NXLxXG85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jWZ2lEPTB;MD6zN|k6QSEQvF2= MU\TRW5ITVJ?
MC-IXC MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojDTWM2OD1yLkO0OUDPxE1? MkfVV2FPT0WU
NCI-H2405 MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7yeFdKSzVyPUCuN|Q4OzJizszN NEnFTWhUSU6JRWK=
NCI-H2009 M1zrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr5SlRKSzVyPUCuN|Q4OzlizszN NGniXmpUSU6JRWK=
LB1047-RCC NFPxVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK1dpRKSzVyPUCuN|U5OTVizszN NX;LOZNGW0GQR1XS
KNS-81-FD NXj4RpM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILwcJNKSzVyPUCuN|Y3PjdizszN NXTwOo9vW0GQR1XS
HOP-92 M4nqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjmTWM2OD1yLkO2PFMh|ryP MVLTRW5ITVJ?
L-428 M3PWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2eycmlEPTB;MD6zO|AyPiEQvF2= Mmm3V2FPT0WU
C3A M4HFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvLTWM2OD1yLkO3N|c6KM7:TR?= Mlj5V2FPT0WU
NCI-H1792 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwM{e2OVUh|ryP NFvVSnRUSU6JRWK=
HuH-7 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO1SW1WUUN3ME2wMlM4QTFizszN NVni[2dxW0GQR1XS
AGS NFuxbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInmZ3VKSzVyPUCuN|g3OzhizszN M3zHXnNCVkeHUh?=
HT-1197 M2PFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwM{m0OkDPxE1? M3jjU3NCVkeHUh?=
CGTH-W-1 M1zx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwM{m5NVMh|ryP NHTrR4xUSU6JRWK=
KNS-42 NXfQVGxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\vTWM2OD1yLkSwNFQ2KM7:TR?= M3jQXnNCVkeHUh?=
HuO-3N1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrTTWM2OD1yLkSwNFU2KM7:TR?= M2rBZnNCVkeHUh?=
VMRC-RCZ MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PDS2lEPTB;MD60NFMxOyEQvF2= M2nMbnNCVkeHUh?=
SW954 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;TWW5KSzVyPUCuOFA{OzVizszN M{LEUnNCVkeHUh?=
MES-SA MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwNEC1NFUh|ryP MorWV2FPT0WU
Ca-Ski MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPpRZFKSzVyPUCuOFA2OjRizszN M3fzPXNCVkeHUh?=
SW13 NHPrWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwNEC2NlYh|ryP NHPIVlVUSU6JRWK=
NCI-H1437 Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW5e3hUUUN3ME2wMlQxQDB3IN88US=> NILpZVVUSU6JRWK=
U-118-MG MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwNEC5NFQh|ryP MUDTRW5ITVJ?
NCI-H1734 M2HHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXToTmdjUUN3ME2wMlQzODF|IN88US=> MV;TRW5ITVJ?
HDLM-2 M3;yWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwNEKwN|Mh|ryP NYC3b3NxW0GQR1XS
AU565 NHfLS2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvITWM2OD1yLkSyOFY5KM7:TR?= NX3wbnBbW0GQR1XS
FADU Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor6TWM2OD1yLkSyOlQ6KM7:TR?= Mm\hV2FPT0WU
OS-RC-2 MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HBe2lEPTB;MD60N|A5OyEQvF2= M3Tv[HNCVkeHUh?=
CAMA-1 NETUVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwNEO2NlYh|ryP MX\TRW5ITVJ?
MONO-MAC-6 M3jNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjVTWM2OD1yLkSzPFQ6KM7:TR?= MVvTRW5ITVJ?
LB831-BLC M2X3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwNESzO|Eh|ryP M37JeHNCVkeHUh?=
SW982 M4LM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHkdVFKSzVyPUCuOFQ2OjhizszN M{f4[HNCVkeHUh?=
SCC-3 MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwNES1O|kh|ryP NIPmUXhUSU6JRWK=
C32 MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PESWlEPTB;MD60OVIzQSEQvF2= NEnQWYZUSU6JRWK=
BFTC-909 NVvSR49GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7m[|I5UUN3ME2wMlQ2Ojl7IN88US=> MkPEV2FPT0WU
MEG-01 NYDQe4N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHleldKSzVyPUCuOFU{PzNizszN NHTqPJFUSU6JRWK=
M14 Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfkOY13UUN3ME2wMlQ2QTd7IN88US=> MkHnV2FPT0WU
MPP-89 NFfOcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjVVHI6UUN3ME2wMlQ3OjV4IN88US=> NX21R5FxW0GQR1XS
HCC1937 Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYOyTlJvUUN3ME2wMlQ3Ozh2IN88US=> M2HlS3NCVkeHUh?=
SW837 NHzqe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f2UGlEPTB;MD60OlczOiEQvF2= NXnO[VZTW0GQR1XS
DU-145 NFLKTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwNE[3Nlkh|ryP NF\ySJdUSU6JRWK=
LB996-RCC M3XyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLxWmlYUUN3ME2wMlQ4ODV2IN88US=> M1XCdXNCVkeHUh?=
C8166 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwNEe0JO69VQ>? NHjpWVFUSU6JRWK=
MOLT-4 M4\5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LYNmlEPTB;MD60O|c{PCEQvF2= NGW1[ZFUSU6JRWK=
DMS-53 NVnadGVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwNEe4NFkh|ryP M3LldXNCVkeHUh?=
TE-5 NXPRRZlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDpUVRKSzVyPUCuOFg{ODVizszN NXP3RZBLW0GQR1XS
KYSE-520 M2LXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK0ZXVKSzVyPUCuOFg{PDNizszN NXTOepgzW0GQR1XS
Detroit562 MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjrXlhXUUN3ME2wMlQ5QDZizszN NV\NZ|BHW0GQR1XS
SIMA NYe2TlNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LVcmlEPTB;MD60PVQyPyEQvF2= MkDEV2FPT0WU
NCI-H1651 NFq0[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrPe4hKSzVyPUCuOFk3PyEQvF2= M3O4T3NCVkeHUh?=
HCC1599 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPJboFKSzVyPUCuOFk6PTVizszN M1\sN3NCVkeHUh?=
ABC-1 NULMWoRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33PZ2lEPTB;MD61NFQ6PiEQvF2= NHXYXHlUSU6JRWK=
CAL-33 MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwNUC4OFQh|ryP MV3TRW5ITVJ?
OPM-2 Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfDdI9KSzVyPUCuOVA6OzdizszN NFLYSGJUSU6JRWK=
RPMI-7951 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnoSG5IUUN3ME2wMlUxQTV5IN88US=> Mlv0V2FPT0WU
HT-1080 MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;6U2NXUUN3ME2wMlUyOTF7IN88US=> NXjJWWwyW0GQR1XS
LC4-1 M1vtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwNUG0NFMh|ryP MlnoV2FPT0WU
OVCAR-3 M2T3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInGOWhKSzVyPUCuOVE2PyEQvF2= MmrUV2FPT0WU
CAPAN-1 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXpW|NUUUN3ME2wMlUzOjh6IN88US=> Ml[2V2FPT0WU
SK-OV-3 M3TpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwNUK0N|Qh|ryP M2LvNHNCVkeHUh?=
HuP-T3 MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;zVZVlUUN3ME2wMlUzQDJ5IN88US=> NXvxZ4s3W0GQR1XS
NCI-H838 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\BTWM2OD1yLkWyPFQ6KM7:TR?= MV7TRW5ITVJ?
K5 NGjkb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\2dXhnUUN3ME2wMlU{OjBzIN88US=> MVLTRW5ITVJ?
CAL-72 NW\VZZZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjPZ3h7UUN3ME2wMlU{Ozh5IN88US=> NGPrPFNUSU6JRWK=
NH-12 NVS0[VNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwNUO5OVkh|ryP MmjtV2FPT0WU
SNB75 NXHrRnVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LUdGlEPTB;MD61OVc{KM7:TR?= MXTTRW5ITVJ?
BPH-1 NVvOeHQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwNU[zOFQh|ryP MYrTRW5ITVJ?
NOMO-1 MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;mUZVxUUN3ME2wMlU3Ozd{IN88US=> Mn3qV2FPT0WU
G-402 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DzbGlEPTB;MD61OlQ6QSEQvF2= M1joTHNCVkeHUh?=
NCI-H2052 NYXEW|VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwNU[3OFEh|ryP M{TnV3NCVkeHUh?=
RCM-1 NXPmb2VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwNUexOlYh|ryP MknSV2FPT0WU
COR-L279 M2XBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfNZXZKSzVyPUCuOVcyQDVizszN NIC3eWhUSU6JRWK=
A253 Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwNUe1NlUh|ryP NF7hZoRUSU6JRWK=
SK-MM-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwNUe2O|kh|ryP NHTWcIFUSU6JRWK=
NCI-H1703 NHfRNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwNUm0Nlch|ryP MVnTRW5ITVJ?
UACC-257 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\jNI5KSzVyPUCuOVk1QDdizszN NWPW[JZoW0GQR1XS
KALS-1 NFy0V3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK1W2x1UUN3ME2wMlYxODFzIN88US=> NGL1WVNUSU6JRWK=
ES5 NGnpcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fxW2lEPTB;MD62NFQ5KM7:TR?= NXXo[nRWW0GQR1XS
MHH-CALL-2 M1m4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXqy[Y1XUUN3ME2wMlYxQDh6IN88US=> NIS4XnZUSU6JRWK=
ChaGo-K-1 M4XpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j0OGlEPTB;MD62NVIzQSEQvF2= MUDTRW5ITVJ?
TGBC1TKB MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwNkG5PEDPxE1? M33LR3NCVkeHUh?=
KU-19-19 Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwNkS1PFYh|ryP MXPTRW5ITVJ?
COLO-684 NHPX[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[wTWM2OD1yLk[1OlEyKM7:TR?= MXLTRW5ITVJ?
LS-1034 NVnhRm5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vOW2lEPTB;MD62OVgyQSEQvF2= NUDGR25bW0GQR1XS
RT-112 M4[yfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3wTWM2OD1yLk[2OVg4KM7:TR?= MnLOV2FPT0WU
Capan-2 NWLvSWRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwNk[2NlIh|ryP MYHTRW5ITVJ?
HSC-4 M2PkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwNk[2PVgh|ryP MXnTRW5ITVJ?
COLO-824 MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;UTWM2OD1yLk[3PFI{KM7:TR?= NFTWfGtUSU6JRWK=
NCI-H2170 NWCyOWp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvSTWM2OD1yLk[4NlU5KM7:TR?= NHfvOHJUSU6JRWK=
GDM-1 NGHMZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HvZ2lEPTB;MD62PFQ6PCEQvF2= NGjOdW1USU6JRWK=
KP-4 M4C2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rnc2lEPTB;MD62PVU4OyEQvF2= MlnTV2FPT0WU
VA-ES-BJ NWDYNZUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwNkm5PFYh|ryP MWjTRW5ITVJ?
KM-H2 M{K5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwN{CwPVEh|ryP M1PPXnNCVkeHUh?=
HH NHOwV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrjeVVKSzVyPUCuO|A3PjJizszN M{CzfnNCVkeHUh?=
DK-MG NUHIWYF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTtTWM2OD1yLkexNFE3KM7:TR?= NEjGR4FUSU6JRWK=
VM-CUB-1 NH;xVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwN{GyOVkh|ryP MX3TRW5ITVJ?
COLO-829 M37tTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny0TWM2OD1yLkexPVg2KM7:TR?= NEOwPFJUSU6JRWK=
OMC-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnLTWM2OD1yLkeyNVA1KM7:TR?= M3TicHNCVkeHUh?=
NB12 MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLiNHcxUUN3ME2wMlczPTB2IN88US=> M2HLUXNCVkeHUh?=
NCI-H28 M4\aPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrCTWM2OD1yLke0NFg{KM7:TR?= MnXHV2FPT0WU
A673 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLyTWM2OD1yLke1NVc4KM7:TR?= MlrHV2FPT0WU
LB2241-RCC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwN{[wPFch|ryP NEnz[3JUSU6JRWK=
CCRF-CEM M1jndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7aeYdPUUN3ME2wMlc4ODV{IN88US=> NELzVo5USU6JRWK=
NCI-H510A NIXnNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSwW3ZKSzVyPUCuO|cyQDZizszN NUjXdXRRW0GQR1XS
SW48 NFrWNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP5TWM2OD1yLke3N|M{KM7:TR?= NHHHW5NUSU6JRWK=
NCI-H2081 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwN{ixOFch|ryP M2C3UXNCVkeHUh?=
RMG-I NILZW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{mwVWlEPTB;MD63PFIyOiEQvF2= MU\TRW5ITVJ?
LU-99A MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwN{i0NVMh|ryP MnezV2FPT0WU
KP-N-YS NWrqR3ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwN{i5NlEh|ryP NEDiRllUSU6JRWK=
MDA-MB-231 NUH5fIVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwOECxN|Eh|ryP NVzUbY5DW0GQR1XS
U031 MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwOEG0NlMh|ryP MX3TRW5ITVJ?
EVSA-T M4\ON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLlTWM2OD1yLkixOlczKM7:TR?= MWXTRW5ITVJ?
MDA-MB-157 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vzUWlEPTB;MD64NlI4OSEQvF2= M4TsOnNCVkeHUh?=
EHEB NWDL[XFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:0TWM2OD1yLkiyNlc3KM7:TR?= NH[5Zm5USU6JRWK=
KINGS-1 NILZVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEC5cpJKSzVyPUCuPFI2PTVizszN Mny2V2FPT0WU
23132-87 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwOEK4OFMh|ryP M1PiNnNCVkeHUh?=
EFO-21 NIr1NWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwOESwPFkh|ryP NUPSUIozW0GQR1XS
DOK NIW2WZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLpTphKSzVyPUCuPFQ5KM7:TR?= Mm\tV2FPT0WU
NCI-H2171 MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwOES5OkDPxE1? NF[3c3RUSU6JRWK=
NCI-SNU-5 NYXFcI5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\6R3V3UUN3ME2wMlg2PTdizszN NWrxcm5MW0GQR1XS
SK-N-DZ MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq4TWM2OD1yLki1PVQ{KM7:TR?= NWnZTno2W0GQR1XS
SNU-C2B MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M131bmlEPTB;MD64OlgxOSEQvF2= MWLTRW5ITVJ?
CP66-MEL NE\PTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[3TWM2OD1yLki3NVEh|ryP NFTqb|dUSU6JRWK=
SN12C M2X3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\ybWlEPTB;MD64PFY{PyEQvF2= NIDXXpFUSU6JRWK=
A172 MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H2S2lEPTB;MD64PFY6QCEQvF2= NYO2eo45W0GQR1XS
NCI-H2347 M3\WUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwOEi3OVMh|ryP M4XlO3NCVkeHUh?=
NCI-H2228 NHXDdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37IXWlEPTB;MD64PVM{QSEQvF2= NWL4UVhvW0GQR1XS
SNU-387 M1zEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwOUCyOlQh|ryP M4jyZXNCVkeHUh?=
SK-MEL-24 NUjQSpZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHoXYZKSzVyPUCuPVE{PDRizszN NULV[o9nW0GQR1XS
MDA-MB-468 NXTNbZlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HLVWlEPTB;MD65NVc{KM7:TR?= NHPlUXFUSU6JRWK=
NCI-H1694 NFHaWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGOxUVRKSzVyPUCuPVE5PzZizszN MVPTRW5ITVJ?
CCF-STTG1 M2f2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn2TWM2OD1yLkmyOlM4KM7:TR?= MWXTRW5ITVJ?
K052 NYHIOnQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HhRWlEPTB;MD65OFA1PyEQvF2= MYrTRW5ITVJ?
NCI-H446 NUPvZ5c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\zcI9WUUN3ME2wMlk2ODFizszN NYjDd3EyW0GQR1XS
MFE-280 M3j1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX5TWM2OD1yLkm2NlkyKM7:TR?= M2O0TXNCVkeHUh?=
KU812 Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[0eolKSzVyPUCuPVk{QDlizszN MoDwV2FPT0WU
MDA-MB-361 M1L4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwOUm3O|ch|ryP NEXYV3FUSU6JRWK=
Raji MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XWPGlEPTB;MT6wNlI3PyEQvF2= Mn3EV2FPT0WU
TE-6 NVLFdFJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX5TWM2OD1zLkCzOVY3KM7:TR?= MmHHV2FPT0WU
CAL-148 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf0TWM2OD1zLkC0OFQ{KM7:TR?= MoDuV2FPT0WU
NCI-H1963 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3i3dmlEPTB;MT6wOFU2OyEQvF2= MX3TRW5ITVJ?
SK-N-AS M4LDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW0RZpKSzVyPUGuNFQ3QDVizszN MYnTRW5ITVJ?
RERF-LC-MS MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFwME[zOFkh|ryP NFzQ[IxUSU6JRWK=
BEN MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS2fnFEUUN3ME2xMlA4OTN5IN88US=> NHWzRYdUSU6JRWK=
CAS-1 Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwMEmxNlMh|ryP NIjyWlNUSU6JRWK=
SW780 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFwMEmxPFEh|ryP NUW2d|JrW0GQR1XS
LU-65 NX7uRZZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHXTWM2OD1zLkC5OFEh|ryP M3[3dXNCVkeHUh?=
D-283MED M4[1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFwMUKyO|Ih|ryP NHnNW3ZUSU6JRWK=
HCC2157 NHLMO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor3TWM2OD1zLkGzOlQzKM7:TR?= NXLlVFZbW0GQR1XS
RCC10RGB NGnwfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFwMUSwNFYh|ryP NV3HT2xTW0GQR1XS
PLC-PRF-5 NHnCNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzrfpdKSzVyPUGuNVUzOjlizszN NXP6XHBxW0GQR1XS
H4 MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFwMUW0N|kh|ryP NUnUTY5kW0GQR1XS
TUR MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwMUW3OVIh|ryP MX3TRW5ITVJ?
NCI-H2141 Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHHTWM2OD1zLkG4PVQ3KM7:TR?= MX\TRW5ITVJ?
PFSK-1 NWf5To9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf6VXRzUUN3ME2xMlIxPTN{IN88US=> NUTseXNnW0GQR1XS
SK-MEL-28 NV36cYduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXGUItPUUN3ME2xMlI{OjJzIN88US=> M{f2[3NCVkeHUh?=
SCC-9 MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\YfGlEPTB;MT6yN|Y3PSEQvF2= NHrQVYJUSU6JRWK=
T47D NEj5SJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT3cIZNUUN3ME2xMlI{Pjl4IN88US=> M4TXN3NCVkeHUh?=
TCCSUP M1nvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXZTWM2OD1zLkK1NFI6KM7:TR?= NHH0V4RUSU6JRWK=
SU-DHL-1 NV;LZYtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTFwMkWxNVgh|ryP NWLIRYI2W0GQR1XS
HL-60 NHLSVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLhTWM2OD1zLkK1OVg5KM7:TR?= NW\iW5VNW0GQR1XS
NCI-H1436 M2nncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGyeYhKSzVyPUGuNlYyPDlizszN MkLYV2FPT0WU
DMS-114 NVjHOZRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\LT3ZKSzVyPUGuNlY3OzJizszN MUPTRW5ITVJ?
BOKU MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFwMkiwPVUh|ryP M4LyRnNCVkeHUh?=
MS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFwMkmwOlkh|ryP NGHZemNUSU6JRWK=
NCI-H661 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;WdWlEPTB;MT6zNFQ4QCEQvF2= M37sfXNCVkeHUh?=
HT-3 MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm3RWNiUUN3ME2xMlMxPTJ7IN88US=> NEPkfHJUSU6JRWK=
CAL-54 NVXPfJN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS2TWM2OD1zLkOwO|I2KM7:TR?= NXHEPHRCW0GQR1XS
SW1463 NXPHb3NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwM{G4O|Ih|ryP MlLEV2FPT0WU
COLO-668 M{XKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\lPGlEPTB;MT6zN|A2PiEQvF2= NGHmSXRUSU6JRWK=
PANC-08-13 M1\ofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjrZ5pmUUN3ME2xMlM{QDB|IN88US=> M3r0PHNCVkeHUh?=
BB49-HNC MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDRcnpKSzVyPUGuN|QxOSEQvF2= MYDTRW5ITVJ?
M059J MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fTPWlEPTB;MT6zOVg{OiEQvF2= MlznV2FPT0WU
NCCIT MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmntTWM2OD1zLkO3PVg5KM7:TR?= NEPn[JdUSU6JRWK=
LN-405 MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjOWWN5UUN3ME2xMlM6OjZ2IN88US=> MnvRV2FPT0WU
UMC-11 Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LIOGlEPTB;MT6zPVk6PiEQvF2= MWPTRW5ITVJ?
NB5 MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTFwNEGyNlch|ryP NX7oZXNJW0GQR1XS
TE-441-T NV;hTGpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\ueGlEPTB;MT60NlgyPyEQvF2= MlvhV2FPT0WU
ME-180 NXXFWZhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe5e3h3UUN3ME2xMlQ1Ozl{IN88US=> MU\TRW5ITVJ?
HCC70 M1npVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTFwNE[wPVYh|ryP NITte25USU6JRWK=
no-10 M4SyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\iNWVKSzVyPUGuOFYyQDFizszN NHHmNlFUSU6JRWK=
JEG-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFwNUCxN|Ih|ryP M3jEdnNCVkeHUh?=
no-11 MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfNT3dpUUN3ME2xMlUxQDh{IN88US=> M37hbXNCVkeHUh?=
CHP-126 NEL2fZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rsW2lEPTB;MT61OlY6OSEQvF2= NHvWS2NUSU6JRWK=
EGI-1 NF;sWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DUemlEPTB;MT61PFAzPSEQvF2= MYnTRW5ITVJ?
D-392MG MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f3[GlEPTB;MT61PVY{KM7:TR?= MojuV2FPT0WU
RT4 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrreHZKSzVyPUGuOVk3OzdizszN Mn3OV2FPT0WU
A204 Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvCbW9KSzVyPUGuOVk5ODFizszN NUXNcFB{W0GQR1XS
NCI-H1304 NHXpU|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnucpJKSzVyPUGuOlM2QTFizszN NIGwZVFUSU6JRWK=
Becker MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzI[nRMUUN3ME2xMlY1OjRzIN88US=> MUPTRW5ITVJ?
OE19 NFjUZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe4O2lKSzVyPUGuOlU2OThizszN NV\Fb|B{W0GQR1XS
EKVX NGjtflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTvW3dZUUN3ME2xMlY2PjF6IN88US=> NXzZTZlrW0GQR1XS
KLE MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vmVWlEPTB;MT62OVcyPCEQvF2= M3XjSHNCVkeHUh?=
K-562 Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;WeXZKSzVyPUGuOlcxOzdizszN NG\BNXFUSU6JRWK=
MDA-MB-175-VII NGjCVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;PTWM2OD1zLk[4PVk4KM7:TR?= MmfTV2FPT0WU
NCI-H716 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H3eGlEPTB;MT62PVMxPCEQvF2= MmexV2FPT0WU
Caov-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTFwNkm0NVMh|ryP NXLuZVF5W0GQR1XS
HCC1187 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD6OFA3UUN3ME2xMlcxPTR3IN88US=> M4fMSHNCVkeHUh?=
CAKI-1 M{LGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S2dGlEPTB;MT63NlI6OiEQvF2= MV;TRW5ITVJ?
MOLT-16 Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFwN{OzNFch|ryP NWPBdFVtW0GQR1XS
PC-3 NUC1XZZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEm3WmZKSzVyPUGuO|UxQCEQvF2= NF;kW5lUSU6JRWK=
DV-90 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;0fGlEPTB;MT63OVU5PSEQvF2= NIDIR2ZUSU6JRWK=
RXF393 NEPrV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\R[Wd5UUN3ME2xMlc4Ojl2IN88US=> NWLzc5Z2W0GQR1XS
SK-NEP-1 Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO5bVRKSzVyPUGuPFI{OzlizszN NWi2NVZQW0GQR1XS
HCC1419 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfUTWM2OD1zLkiyOlkzKM7:TR?= MmPUV2FPT0WU
BV-173 NWjVeJlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LRe2lEPTB;MT64Nlk6PSEQvF2= M4TMcHNCVkeHUh?=
MKN7 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XIZmlEPTB;MT64PVIzKM7:TR?= M4n4VHNCVkeHUh?=
LAN-6 M37SRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkm5TWM2OD1zLki5OVU{KM7:TR?= M1r5dnNCVkeHUh?=
Mo-T M2DvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvSSFE1UUN3ME2xMlkxODN7IN88US=> NGTUNGNUSU6JRWK=
HCC1395 Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFwOUK4OlMh|ryP M{\JV3NCVkeHUh?=
HC-1 M{flTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWryOZhFUUN3ME2xMlk{PDdizszN M2\KZnNCVkeHUh?=
HPAF-II MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFwOUS0NVgh|ryP M{fLXXNCVkeHUh?=
CPC-N NXj2U5RxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vkOGlEPTB;MT65PFAxOiEQvF2= MYDTRW5ITVJ?
MKN45 NUn0TIRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP2OXB3UUN3ME2xMlk6OTF7IN88US=> NHrPbGFUSU6JRWK=
NCI-H1693 M1S0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJwMEC0N|Mh|ryP M{fOPXNCVkeHUh?=
SHP-77 M1rxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHCb25GUUN3ME2yMlAxPTN|IN88US=> MYDTRW5ITVJ?
NCI-H1522 NELGdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJwMEG3NlQh|ryP MYHTRW5ITVJ?
SW1573 NHPuXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHjRWZnUUN3ME2yMlAzOiEQvF2= Mm\iV2FPT0WU
DBTRG-05MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHZWGhCUUN3ME2yMlA3ODh5IN88US=> MUDTRW5ITVJ?
SCC-4 MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXPXYpKSzVyPUKuNVQ{OSEQvF2= NGTsTHZUSU6JRWK=
DMS-153 NV7SZ5I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXnS4xKSzVyPUKuNVY3PjhizszN NVfOVYpGW0GQR1XS
MDA-MB-415 NYT5[oU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T5SmlEPTB;Mj6xO|UzKM7:TR?= M2G1R3NCVkeHUh?=
NCI-H2126 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJwMkK4PFgh|ryP MV7TRW5ITVJ?
MDA-MB-453 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJwMkOzNkDPxE1? M{HFNnNCVkeHUh?=
U-87-MG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJwMki1PVIh|ryP MnfaV2FPT0WU
LNCaP-Clone-FGC M{nudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHGTWM2OD1{LkOwNVAzKM7:TR?= MnuzV2FPT0WU
NCI-H1581 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz5coRKSzVyPUKuN|IyODVizszN MUfTRW5ITVJ?
BC-3 NEnKZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJwM{[1NFkh|ryP NWHsXo9RW0GQR1XS
HCC38 NHrGZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1j5dmlEPTB;Mj6zPFQ1PyEQvF2= NWLFRos3W0GQR1XS
HCC2218 MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJwNEC4NFkh|ryP MYLTRW5ITVJ?
RO82-W-1 NXv1R2dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJwNEGyOUDPxE1? NUm5SnltW0GQR1XS
C2BBe1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDxTWM2OD1{LkSxOVc5KM7:TR?= Mnu4V2FPT0WU
LAMA-84 MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTITWM2OD1{LkW3N|Y5KM7:TR?= M13RSnNCVkeHUh?=
GMS-10 NV3mN21nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOyTWM2OD1{LkW3OlEyKM7:TR?= MlvSV2FPT0WU
GCT Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYroeVhNUUN3ME2yMlU5Pjl2IN88US=> M1jWR3NCVkeHUh?=
SK-CO-1 NUHBOXJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJwNkG2OkDPxE1? MUDTRW5ITVJ?
NCI-H526 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPRTWM2OD1{Lk[zOFUh|ryP NFu3b3pUSU6JRWK=
SW1088 NInURYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJwN{e4N|kh|ryP NYDSN25DW0GQR1XS
HT55 MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLtTWM2OD1{Lke4Olk2KM7:TR?= MlOxV2FPT0WU
NB10 M3zScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPPW|Z{UUN3ME2yMlgyPzR6IN88US=> MlTzV2FPT0WU
UACC-893 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Pv[2lEPTB;Mj64OVc1QSEQvF2= M2K4T3NCVkeHUh?=
NCI-H1618 NVXjXnpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHNTWM2OD1{Lki4NVU{KM7:TR?= M4jabHNCVkeHUh?=
NCI-H1092 NX:5VHFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTNwMEe4NVIh|ryP NUK3XG95W0GQR1XS
SBC-1 M{XVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTNwMEi1OVMh|ryP M3fyU3NCVkeHUh?=
NCI-H1623 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHzT3NKSzVyPUOuNFk{PCEQvF2= M{DURXNCVkeHUh?=
SiHa Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:4fG5KSzVyPUOuNVE6PzdizszN NF;zNpFUSU6JRWK=
D-263MG M2TYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTNwMUS3PFgh|ryP M{\CfXNCVkeHUh?=
NCI-H1573 NFr4eWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPBTWM2OD1|LkG5OlQyKM7:TR?= M2TpUXNCVkeHUh?=
NCI-H82 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\UelRKSzVyPUOuN|Q1OzlizszN M3jLd3NCVkeHUh?=
NCI-H2196 NXzKc5Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\jWW14UUN3ME2zMlM2ODB6IN88US=> NUnpSllmW0GQR1XS
MFM-223 NXu1TFFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof2TWM2OD1|LkO3N|UyKM7:TR?= NF\3TI9USU6JRWK=
COLO-678 MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTNwM{ixPFYh|ryP MV\TRW5ITVJ?
EW-3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrER45KSzVyPUOuOFA6PSEQvF2= NX7ZVXV1W0GQR1XS
MHH-NB-11 M1n4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTFTWM2OD1|LkS0NFY6KM7:TR?= MXXTRW5ITVJ?
EM-2 MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTNwNkO5PEDPxE1? M4jDfXNCVkeHUh?=
FTC-133 M3Ozb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDBTWM2OD1|Lk[1OFU5KM7:TR?= MVvTRW5ITVJ?
NCI-H209 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPBTWM2OD1|Lk[3OlU{KM7:TR?= M3fjdXNCVkeHUh?=
TGBC24TKB M3e2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDCRZVKSzVyPUOuOlg{PTVizszN MnnJV2FPT0WU
LC-1F MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:yTWM2OD1|LkexO|Y1KM7:TR?= NH7YcWpUSU6JRWK=
C-4-II NGnkc25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3ZNVRMUUN3ME2zMlc2PjR|IN88US=> NH7LXJNUSU6JRWK=
NCI-H1650 M2Dkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PzWmlEPTB;Mz63PFQ2PSEQvF2= NVu2VnFvW0GQR1XS
JVM-2 NWTkTGN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnMZ3dKSzVyPUOuPVM3OzlizszN NYnlR4dYW0GQR1XS
CaR-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz4TWM2OD1|Lkm3OlE4KM7:TR?= M2fpZnNCVkeHUh?=
MDA-MB-134-VI MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTRwMEK5OVIh|ryP MY\TRW5ITVJ?
NCI-H719 MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPFXnJJUUN3ME20MlE2Ozh6IN88US=> MV3TRW5ITVJ?
GOTO M1i2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7XS25KSzVyPUSuNlk4ODVizszN MlThV2FPT0WU
NCI-N87 MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIqxfHBKSzVyPUSuN|g5OjFizszN NF20XmxUSU6JRWK=
NB6 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjadJhKSzVyPUSuOFI2ODlizszN MnHTV2FPT0WU
DSH1 NGHmbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33NeGlEPTB;ND60O|EyPiEQvF2= NV7aV5JCW0GQR1XS
BT-20 M4roRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvXRXJKSzVyPUSuOFkxODJizszN MofHV2FPT0WU
NCI-H1882 M1L4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nEd2lEPTB;ND61NFU4KM7:TR?= NH[5UHVUSU6JRWK=
WM-115 NUPQSWZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\ufoo1UUN3ME20MlUxQDhzIN88US=> MlW1V2FPT0WU
SKG-IIIa MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzOTWM2OD12Lk[3O|ch|ryP MnP3V2FPT0WU
NCI-H69 NEnmTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\BeGlEPTB;ND63NFI4PSEQvF2= M4jSXXNCVkeHUh?=
MSTO-211H MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG3TWM2OD12LkizOVY2KM7:TR?= NXHGXFFTW0GQR1XS
Mewo NWnycXVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XSXmlEPTB;ND65OlMyOyEQvF2= NFP0SZhUSU6JRWK=
GI-ME-N NXTUdJRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInrbGtKSzVyPUWuNFA2ODlizszN MXjTRW5ITVJ?
T98G MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXUXJYzUUN3ME21MlA3PTB6IN88US=> NH:5WGRUSU6JRWK=
ECC4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXOxRplnUUN3ME21MlA6Ozd{IN88US=> M4DMU3NCVkeHUh?=
EW-11 M1vEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf5[XVKSzVyPUWuNVgxQTlizszN MXrTRW5ITVJ?
COLO-800 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXuxN45{UUN3ME21MlE6OzR7IN88US=> NIPn[o5USU6JRWK=
NCI-H1755 MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3zfIZXUUN3ME21MlI{ODJ5IN88US=> NGi3eHdUSU6JRWK=
KMS-12-PE MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;LfJNKSzVyPUWuN|UxQDVizszN MmfqV2FPT0WU
HCC1954 NVHJ[GJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmToTWM2OD13Lki1PVcyKM7:TR?= Mk\SV2FPT0WU
NCI-H187 NYPuZnduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTVwOUK5PFkh|ryP NILoW3JUSU6JRWK=
LU-165 NGS1N3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jRO2lEPTB;NT65PVAxOiEQvF2= NF\ybZZUSU6JRWK=
YAPC MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfZcnZFUUN3ME21Mlk6ODZ6IN88US=> Mn\6V2FPT0WU
LU-139 NYfHb2dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vBNWlEPTB;Nj6wPFM3QCEQvF2= NHrDOWVUSU6JRWK=
D-502MG M376OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13PTmlEPTB;Nj6zNlA1PyEQvF2= MVTTRW5ITVJ?
IST-SL1 MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP6clRKSzVyPU[uOVM6PDhizszN MWPTRW5ITVJ?
DG-75 M13zdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvuTIZKSzVyPU[uPFg4QDZizszN MoLMV2FPT0WU
NCI-H1155 MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TmfWlEPTB;Nj65OVU5OSEQvF2= NHflOnZUSU6JRWK=
EFE-184 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTdwM{G2PVUh|ryP NX;J[IZQW0GQR1XS
AsPC-1 NXrVeGh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;zfGRKSzVyPUeuOFg5ODdizszN M2fhZ3NCVkeHUh?=
SW948 M{nH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTdwNUizPVUh|ryP MXnTRW5ITVJ?
NCI-H524 NVWyU|F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHmdG1KSzVyPUmuOVg3OjhizszN M3G3XHNCVkeHUh?=
KOSC-2 M1i5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDOTWM2OD17Lk[yPFM1KM7:TR?= NYHpUoZZW0GQR1XS
T-24 M3[0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonCTWM2OD17Lkm0OFE2KM7:TR?= NEHTXZVUSU6JRWK=
NCI-H748 MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFyLk[zPVch|ryP M3rzZnNCVkeHUh?=
NCI-H23 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v4SGlEPTB;MUCuOlQ1OiEQvF2= MkfPV2FPT0WU
UACC-812 NEjYZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnFTWM2OD1zMT63NVch|ryP NIjQdHdUSU6JRWK=
SCLC-21H MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjRTpZtUUN3ME2xNk4yPTVzIN88US=> NUO1UoN1W0GQR1XS
NCI-SNU-16 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfQTnVbUUN3ME2xN{4yOjV6IN88US=> NXO5R4cyW0GQR1XS
HD-MY-Z NVfjbllvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPVTWM2OD1zND62N|Y{KM7:TR?= NHzIeoxUSU6JRWK=
SK-N-FI Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;wO2d3UUN3ME2xOE45QTF{IN88US=> MorQV2FPT0WU
LB647-SCLC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLaO4RmUUN3ME2xOU44OTl3IN88US=> MWLTRW5ITVJ?
NCI-H345 M3L0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqyOXRKSzVyPUG3MlM1OyEQvF2= NVzBS3BXW0GQR1XS
NCI-H1563 M1;Zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF6Lke2NFEh|ryP MUDTRW5ITVJ?
RL NYHSeYRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrnTWM2OD1{MT6yOlU3KM7:TR?= MVPTRW5ITVJ?
KY821 Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJ{LkC1OVMh|ryP NVSyV2JZW0GQR1XS
JVM-3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJ3LkC0NVMh|ryP NUjwVI5uW0GQR1XS
NCI-H1793 MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIW1Z4xKSzVyPUK4MlU1QTlizszN MlGzV2FPT0WU
LU-134-A NH20T2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:yNmlEPTB;M{CuNlA{PyEQvF2= M4HqWnNCVkeHUh?=
NCI-H1395 NYX3eldTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j4RWlEPTB;M{KuNlQ{OSEQvF2= NWfXZVhpW0GQR1XS
NCI-H1993 NWjBdXUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fCbmlEPTB;M{KuPFIyQCEQvF2= NFvEV2tUSU6JRWK=
P31-FUJ NGnPO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETaNmlKSzVyPUOzMlQ5QTlizszN M4LqPXNCVkeHUh?=
LS-513 NUHXSGg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLhNohxUUN3ME2zOU45QDd7IN88US=> MlXzV2FPT0WU
SK-MEL-1 M13Kemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fkb2lEPTB;NECuN|Q6QSEQvF2= M{P6T3NCVkeHUh?=
SW684 NGrXbHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnZVXNGUUN3ME20N{46PjZzIN88US=> MXrTRW5ITVJ?
COR-L88 NF;ZWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;NPI5KSzVyPUS0MlA3PjVizszN MoP6V2FPT0WU
NCI-H889 NIm1OmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTR3LkCwPFch|ryP NFrXbmtUSU6JRWK=
TALL-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTR4LkGxPVkh|ryP NEPIflFUSU6JRWK=
KARPAS-299 M1LhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPFXIdjUUN3ME20O{4yQTl|IN88US=> M2WyXHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. [1]

Protocol

Kinase Assay:[1]
+ Expand

Bcl-2 Binding affinity calculation:

A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. [4] As a control in determining the reliability of the calculation, predicted binding affinities Ki) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:[2]
+ Expand
  • Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs)
  • Concentrations: ~10 μM
  • Incubation Time: 48-72 hours
  • Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 104 per well for HMCLs or 5~10 × 103 for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used.
  • Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m
  • Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg
  • Administration: Administered intravenously (tail vein) once a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL (200.73 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 413.49
Formula

C20H19N3O.CH4O3S

CAS No. 803712-79-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01563601 Withdrawn Extensive-stage Small Cell Lung Cancer Cephalon|Teva Pharmaceutical Industries August 2012 Phase 3
NCT01238146 Withdrawn Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma National Cancer Institute (NCI) October 2010 Phase 1|Phase 2
NCT01150656 Completed Leukemia Children''s Oncology Group|National Cancer Institute (NCI) June 2010 --
NCT00933985 Terminated Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Unspecified Childhood Solid Tumor Protocol Specific National Cancer Institute (NCI) June 2009 Phase 1
NCT00521144 Completed Recurrent Small Cell Lung Cancer|Unspecified Adult Solid Tumor Protocol Specific National Cancer Institute (NCI) August 2007 Phase 1|Phase 2
NCT00427856 Completed Lymphoma Follicular Gemin X|Teva Pharmaceutical Industries March 2007 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Tags: buy Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) supplier | purchase Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) cost | Obatoclax Mesylate (GX15-070) manufacturer | order Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID